title: Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease Prognosis.
abstract: The PAX8/PPARγ fusion protein (PPFP) occurs in 36% of human follicular thyroid carcinoma (FTC) and is associated with favorable prognosis. To elucidate the function of PPFP in FTC, we analyzed the consequences of PPFP expression in immortalized thyrocytes in vitro and in vivo via xenograft tumorigenesis. While PPFP-expressing cells exhibited oncogenic hallmarks, including increased growth and decreased apoptosis, in vitro, xenograft tumors were initiated but not sustained in vivo. PPFP xenograft tumors exhibited reduced CD31 staining and VEGF expression, suggesting that PPFP modulates neovascularization. Microarray analysis demonstrated increased expression of tissue inhibitor of metalloproteinase (TIMP-3), an inhibitor of angiogenesis, in PPFP cells and tumors, a finding confirmed by quantitative PCR and immunohistochemistry. Immunohistochemical staining of archival human thyroid tumors demonstrates a significant decrease in CD31 staining in all adenomas and carcinomas containing the PAX8/PPARγ rearrangement. Decreased angiogenesis in PPFP-containing tumors is directly correlated with our observations in the xenograft model and provides evidence for the first time that PPFP may impact FTC tumorigenesis by modulating angiogenesis in vivo.
authors.affiliation: Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: H V
authors.initials: HV
authors.lastname: Reddi
authors.forename: P
authors.initials: P
authors.lastname: Madde
authors.forename: L A
authors.initials: LA
authors.lastname: Marlow
authors.forename: J A
authors.initials: JA
authors.lastname: Copland
authors.forename: B
authors.initials: B
authors.lastname: McIver
authors.forename: S K G
authors.initials: SK
authors.lastname: Grebe
authors.forename: N L
authors.initials: NL
authors.lastname: Eberhardt
references.citation: Angiogenesis. 2005;8(4):373-9
references.pmid: 16400517
references.citation: Biochem Cell Biol. 1996;74(6):853-62
references.pmid: 9164653
references.citation: Clin Endocrinol (Oxf). 2007 Nov;67(5):706-11
references.pmid: 17651453
references.citation: J Immunol Methods. 1986 May 22;89(2):271-7
references.pmid: 3486233
references.citation: Oncogene. 2005 Nov 21;24(52):7729-45
references.pmid: 16299533
references.citation: Endocrinology. 2006 Jan;147(1):367-76
references.pmid: 16179407
references.citation: Cancer Res. 2008 Jun 15;68(12):4736-45
references.pmid: 18559520
references.citation: Eur J Endocrinol. 2004 Sep;151(3):367-74
references.pmid: 15362967
references.citation: Science. 2000 Aug 25;289(5483):1357-60
references.pmid: 10958784
references.citation: Invest Ophthalmol Vis Sci. 1997 Apr;38(5):817-23
references.pmid: 9112976
references.citation: Thyroid. 2007 Jun;17(6):497-509
references.pmid: 17614769
references.citation: Biochem J. 2006 Sep 15;398(3):515-9
references.pmid: 16771712
references.citation: J Clin Endocrinol Metab. 2003 Jan;88(1):354-7
references.pmid: 12519876
references.citation: Biochem Pharmacol. 2008 Dec 1;76(11):1544-53
references.pmid: 18771658
references.citation: Bull Cancer. 2005 Jan;92(1):37-43
references.pmid: 15689324
references.citation: Am J Pathol. 2003 Apr;162(4):1053-60
references.pmid: 12651598
references.citation: J Biol Chem. 2000 Oct 6;275(40):31226-32
references.pmid: 10900194
references.citation: Nat Genet. 2003 Aug;34(4):369-76
references.pmid: 12923544
references.citation: Mol Cell Endocrinol. 2010 May 28;321(1):50-6
references.pmid: 19883731
references.citation: Nat Med. 2003 Apr;9(4):407-15
references.pmid: 12652295
references.citation: Oncol Rep. 2008 Dec;20(6):1489-95
references.pmid: 19020732
references.citation: Oncogene. 2004 Apr 29;23(20):3634-41
references.pmid: 15077183
references.citation: Int J Cancer. 2003 Oct 10;106(6):848-55
references.pmid: 12918061
references.citation: J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52
references.pmid: 12161538
references.citation: J Surg Oncol. 2006 Dec 15;94(8):662-9
references.pmid: 17131411
references.citation: J Clin Endocrinol Metab. 2005 Jan;90(1):463-8
references.pmid: 15483076
references.citation: Nat Rev Cancer. 2002 Oct;2(10):795-803
references.pmid: 12360282
references.citation: Br J Cancer. 1989 Dec;60(6):897-903
references.pmid: 2557880
references.citation: Thyroid. 2005 May;15(5):422-6
references.pmid: 15929662
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93
references.pmid: 16609007
references.citation: J Exp Med. 1972 Aug 1;136(2):261-76
references.pmid: 5043412
references.citation: Mol Cell Endocrinol. 2010 May 28;321(1):36-43
references.pmid: 19766698
references.citation: Cancer Lett. 2005 Jun 1;223(1):137-42
references.pmid: 15890246
references.citation: Am J Pathol. 2005 Jul;167(1):223-31
references.pmid: 15972966
references.citation: Oncogene. 2005 Feb 17;24(8):1467-76
references.pmid: 15608688
references.citation: Leukemia. 2006 Jan;20(1):1-8
references.pmid: 16281069
references.citation: Semin Cancer Biol. 1992 Apr;3(2):65-71
references.pmid: 1378311
references.citation: J Immunol. 2005 May 15;174(10):6524-31
references.pmid: 15879156
references.citation: Endocrinology. 2009 Sep;150(9):4386-94
references.pmid: 19541765
references.citation: J Virol. 1989 Apr;63(4):1651-60
references.pmid: 2538648
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: J Clin Endocrinol Metab. 2003 May;88(5):2318-26
references.pmid: 12727991
references.citation: PPAR Res. 2008;2008:309469
references.pmid: 18596912
references.citation: J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5
references.pmid: 12970322
references.citation: Int J Cancer. 2006 Nov 15;119(10):2322-9
references.pmid: 16858683
references.citation: Br J Cancer. 2004 Aug 16;91(4):732-8
references.pmid: 15238980